remibrutinib

Novartis MS drug beats standard therapy in two Phase III trials

Novartis announced on Tuesday that its oral BTK inhibitor remibrutinib met the primary endpoint in two Phase III trials in relapsing multiple sclerosis, a result that positions the Swiss drugmaker to file for regulatory approval and strengthens its hand in…